Recruiting
Phase 2

(Neo)Adjuvant IDE196 (Darovasertib) in Patients With Localized Ocular Melanoma

Sponsor:

IDEAYA Biosciences

Code:

NCT05907954

Conditions

Uveal Melanoma

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Darovasertib

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-03-28. This information was provided to ClinicalTrials.gov by IDEAYA Biosciences on 2024-10-28.